OWP Pharmaceuticals, Inc.
$7.8K 412 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Novo Nordisk US Research & Development, Inc.
Novo Nordisk US Research & Development, Inc. reported $7,767.41 across General Payments, Research, and Ownership to 3 physicians and teaching hospitals across 3 transactions.
- $7.8K Below-median payer
- All-tracks total
- 3 Below-median volume
- Transactions
- 3 Below-median reach
- Recipients
- +$7.5K
- General Payments vs PY2023
Novo Nordisk US Research & Development, Inc. reported $7,767.41 across all CMS Open Payments tracks (General + Research + Ownership) to 3 physicians and teaching hospitals in Program Year 2024 - ranking #1663 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $7,767.41, averaging $2.6K per recipient.
Novo Nordisk US Research & Development, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
13/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer novo-nordisk-us-research-development-inc Novo Nordisk US Research & Development, Inc.
$7.8K · #1663/1,925 · 0.0% industry · PY2024
- TOT $7.8K
- RANK #1663
- SHARE 0.0%
- TXN 3
- RCP 3
- CAT 2
- GEN $7.8K
- ΔGEN +$7.5K
- TOP1 69.8%
- PY 2024
Volume peers
Nearest volume peer: OWP Pharmaceuticals, Inc. ($7.8K)
Novo Nordisk US Research & Development, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Novo Nordisk US Research & Development, Inc.'s CMS-reported General Payments increased by $7.5K (+2960.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: NOVO NORDISK US RESEARCH & DEVELOPMENT, INC.PY2023: NOVO NORDISK US RESEARCH & DEVELOPMENT, INC.PY2024: Novo Nordisk US Research & Development, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $253.82
- PY2024
- $7,767.41
What the Data Shows for Novo Nordisk US Research & Development, Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Novo Nordisk US Research & Development, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
2 transactions worth $7.8K make "Consulting Fee" the top general-payment category in the 2-category breakdown below, 99.8% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Consulting Fee" leads Novo Nordisk US Research & Development, Inc.'s 2-category general-payment breakdown at $7.8K, 99.8% of the reported total.
How Novo Nordisk US Research & Development, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $7.8K | 2 | 99.8% |
| Food and Beverage | $17.41 | 1 | 0.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $7,767.41 (100.0%) of $7,767.41 in this company's General Payments records across 3 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Novo Nordisk US Research & Development, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Luigi Adamo
$5,425.00 across 1 reported transactions
- 2
Jonathan S Wilensky
$2,325.00 across 1 reported transactions
- 3
Jonathan G Stine
$17.41 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Novo Nordisk US Research & Development, Inc. ranks #1663 of 1,925 by total payments (bottom 14% by spend) but is notably more concentrated than that alone would suggest -- #277 of 1,838 by HHI (top 15% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Rebiotix Inc. : $114.1K total payments, HHI 5889
- Spark Therapeutics, Inc. : $1.1M total payments, HHI 5876
- Agile Devices, Inc. : $8.4K total payments, HHI 5847
- Hubly Incorporated : $205.53 total payments, HHI 5839
- New York Blood Center, Inc. : $184.6K total payments, HHI 5838
- Mylan Pharmaceuticals Inc. : $379.70 total payments, HHI 5777
- Novo Nordisk US Research & Development, Inc. (this company) : $7.8K total payments, HHI 5774
- Spinevision SAS : $66.0K total payments, HHI 5765
- Cook Medical LLC : $2.8M total payments, HHI 5718
- Channel Medsystems, Inc. : $194.3K total payments, HHI 5715
- Adagio Medical, Inc. : $49.5K total payments, HHI 5713
- Radical Catheter Technologies, Inc. : $15.2K total payments, HHI 5702
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Novo Nordisk US Research & Development, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Novo Nordisk US Research & Development, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Novo Nordisk US Research & Development, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Quest Medical Imaging, Inc
$7.7K 1 recipients
Compare payment profiles
Next Orthosurgical, Inc
$7.7K 7 recipients
Compare payment profiles
Biedermann Motech, Inc.
$7.7K 18 recipients
Compare payment profiles
Kedrion S.p.A.
$7.7K 0 recipients
Compare payment profiles
MeMed US, Inc.
$7.7K 25 recipients
Compare payment profiles
Put this to use
Novo Nordisk US Research & Development, Inc. ranks #1663 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Novo Nordisk US Research & Development, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.